BP
TXG icon

Ballentine Partners’s 10x Genomics TXG Stock Holding History

Ballentine Partners’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$593K Buy
15,455
+20
+0.1% +$524 0.01% 511
2026
Q1 		$328K Buy
15,435
+24
+0.2% +$480 ﹤0.01% 694
2025
Q4 		$251K Sell
15,411
-277
-2% -$4.18K ﹤0.01% 812
2025
Q3 		$183K Buy
15,688
+114
+0.7% +$1.49K ﹤0.01% 935
2025
Q2 		$180K Buy
+15,574
New +$142K ﹤0.01% 894

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ballentine Partners's TXG Position: Q2 2026 in Review

Ballentine Partners increased its 10x Genomics (TXG) stake by 0.13% in Q2 2026, buying an estimated $524 and bringing the position to 15,455 shares worth $593K. The position accounts for 0.01% of the portfolio, ranked #511.

Ballentine Partners first reported a position in TXG in Q2 2025 and has held it in 5 quarters since. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Ballentine Partners held 15,455 shares of 10x Genomics worth $593K as of Q2 2026.
  • Ballentine Partners bought 20 10x Genomics shares in Q2 2026, an estimated $524.
  • 10x Genomics made up 0.01% of Ballentine Partners's portfolio in Q2 2026, its #511 holding.
  • Ballentine Partners first reported a position in 10x Genomics in Q2 2025 and has held it in 5 quarters since.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.